Screener
Halozyme Therapeutics HALO Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Weighted Average Useful Life (in years) | Gross Carrying Value | Accumulated Amortization | Net Carrying Value |
|---|---|---|---|---|
| Auto-injector technology platform | 7 | $402,000 | $235,735 | $166,265 |
| XYOSTED proprietary product | 10 | 136,200 | 55,908 | 80,292 |
| Hypercon developed technology platform | 15 | 230,000 | 9,498 | 220,502 |
| Customer relationships (1) | 15 | 470,000 | 19,410 | 450,590 |
| Trade name | 15 | 5,000 | 206 | 4,794 |
| Total intangible assets, net | $1,243,200 | $320,757 | $922,443 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's finite-lived intangible assets, accumulated amortization?
- Halozyme Therapeutics (HALO) reported finite-lived intangible assets, accumulated amortization of $320.76M in Q2 2026.
- How has Halozyme Therapeutics's finite-lived intangible assets, accumulated amortization changed year-over-year?
- Halozyme Therapeutics's finite-lived intangible assets, accumulated amortization increased by 45.4% year-over-year, from $220.59M to $320.76M.
- What does finite-lived intangible assets, accumulated amortization mean?
- Finite-Lived Intangible Assets, Accumulated Amortization
Ask your AI about Halozyme Therapeutics's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude